Frontage gets FDA chiding over Chinese lab

U.S. CRO Frontage has received a Form 483 from the FDA after an inspection of its bioanalytical lab in Shanghai, in-PharmaTechnologist reports. The note is not a full-on FDA warning letter, and the company says the cited problems are minor and "will be sorted without a problem." Report

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.